Cargando…
Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study
BACKGROUND: Medication for opioid use disorder (MOUD) reduces mortality, but few patients access MOUD. At a Federally Qualified Health Center (FQHC), we implemented a low barrier model of MOUD, including same-day MOUD initiation and a harm reduction philosophy. OBJECTIVE: To investigate whether low...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636799/ https://www.ncbi.nlm.nih.gov/pubmed/36335381 http://dx.doi.org/10.1186/s13722-022-00342-1 |
_version_ | 1784825033442459648 |
---|---|
author | Carter, Jamie Li, Zhen Chen, Hillary Greiner, Melissa Bush, Christopher Bhattacharya, Debanjan Poley, Stephanie Sachdeva, Nidhi Crowder, Jane Carolyn Feigal, Jacob |
author_facet | Carter, Jamie Li, Zhen Chen, Hillary Greiner, Melissa Bush, Christopher Bhattacharya, Debanjan Poley, Stephanie Sachdeva, Nidhi Crowder, Jane Carolyn Feigal, Jacob |
author_sort | Carter, Jamie |
collection | PubMed |
description | BACKGROUND: Medication for opioid use disorder (MOUD) reduces mortality, but few patients access MOUD. At a Federally Qualified Health Center (FQHC), we implemented a low barrier model of MOUD, including same-day MOUD initiation and a harm reduction philosophy. OBJECTIVE: To investigate whether low barrier MOUD improved retention in care compared to traditional treatment. DESIGN AND PARTICIPANTS: Retrospective cohort study of patients with at least one visit seeking MOUD at the FQHC during a historical control period (3/1/2018—3/31/2019) and a low barrier intervention period (11/1/2019—7/31/2020). MAIN MEASURES: Primary outcomes were any MOUD prescription within 6 months of the index visit and 3- and 6-month retention in treatment without care gap, with care gap defined as 60 consecutive days without a visit or prescription. Secondary outcomes were all-cause hospitalization and emergency department visit within 6 months of the index visit. KEY RESULTS: Baseline characteristics were similar between the intervention (n = 113) and control (n = 90) groups, except the intervention group had higher rates of uninsured, public insurance and diabetes. Any MOUD prescription within 6 months of index visit was higher in the intervention group (97.3% vs 70%), with higher adjusted odds of MOUD prescription (OR = 4.01, 95% CI 2.08–7.71). Retention in care was similar between groups at 3 months (61.9% vs 60%, aOR = 1.06, 95% CI 0.78–1.44). At 6 months, a higher proportion of the intervention group was retained in care, but the difference was not statistically significant (53.1% vs 45.6%, aOR 1.27, 95% CI 0.93–1.73). There was no significant difference in adjusted odds of 6-month hospitalization or ED visit between groups. CONCLUSIONS: Low barrier MOUD engaged a higher risk population and did not result in any statistically significant difference in retention in care compared with a historical control. Future research should determine what interventions improve retention of patients engaged through low barrier care. Primary care clinics can implement low barrier treatment to make MOUD accessible to a broader population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13722-022-00342-1. |
format | Online Article Text |
id | pubmed-9636799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96367992022-11-06 Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study Carter, Jamie Li, Zhen Chen, Hillary Greiner, Melissa Bush, Christopher Bhattacharya, Debanjan Poley, Stephanie Sachdeva, Nidhi Crowder, Jane Carolyn Feigal, Jacob Addict Sci Clin Pract Research BACKGROUND: Medication for opioid use disorder (MOUD) reduces mortality, but few patients access MOUD. At a Federally Qualified Health Center (FQHC), we implemented a low barrier model of MOUD, including same-day MOUD initiation and a harm reduction philosophy. OBJECTIVE: To investigate whether low barrier MOUD improved retention in care compared to traditional treatment. DESIGN AND PARTICIPANTS: Retrospective cohort study of patients with at least one visit seeking MOUD at the FQHC during a historical control period (3/1/2018—3/31/2019) and a low barrier intervention period (11/1/2019—7/31/2020). MAIN MEASURES: Primary outcomes were any MOUD prescription within 6 months of the index visit and 3- and 6-month retention in treatment without care gap, with care gap defined as 60 consecutive days without a visit or prescription. Secondary outcomes were all-cause hospitalization and emergency department visit within 6 months of the index visit. KEY RESULTS: Baseline characteristics were similar between the intervention (n = 113) and control (n = 90) groups, except the intervention group had higher rates of uninsured, public insurance and diabetes. Any MOUD prescription within 6 months of index visit was higher in the intervention group (97.3% vs 70%), with higher adjusted odds of MOUD prescription (OR = 4.01, 95% CI 2.08–7.71). Retention in care was similar between groups at 3 months (61.9% vs 60%, aOR = 1.06, 95% CI 0.78–1.44). At 6 months, a higher proportion of the intervention group was retained in care, but the difference was not statistically significant (53.1% vs 45.6%, aOR 1.27, 95% CI 0.93–1.73). There was no significant difference in adjusted odds of 6-month hospitalization or ED visit between groups. CONCLUSIONS: Low barrier MOUD engaged a higher risk population and did not result in any statistically significant difference in retention in care compared with a historical control. Future research should determine what interventions improve retention of patients engaged through low barrier care. Primary care clinics can implement low barrier treatment to make MOUD accessible to a broader population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13722-022-00342-1. BioMed Central 2022-11-05 2022 /pmc/articles/PMC9636799/ /pubmed/36335381 http://dx.doi.org/10.1186/s13722-022-00342-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Carter, Jamie Li, Zhen Chen, Hillary Greiner, Melissa Bush, Christopher Bhattacharya, Debanjan Poley, Stephanie Sachdeva, Nidhi Crowder, Jane Carolyn Feigal, Jacob Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study |
title | Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study |
title_full | Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study |
title_fullStr | Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study |
title_full_unstemmed | Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study |
title_short | Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study |
title_sort | low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636799/ https://www.ncbi.nlm.nih.gov/pubmed/36335381 http://dx.doi.org/10.1186/s13722-022-00342-1 |
work_keys_str_mv | AT carterjamie lowbarriermedicationforopioidusedisorderatafederallyqualifiedhealthcenteraretrospectivecohortstudy AT lizhen lowbarriermedicationforopioidusedisorderatafederallyqualifiedhealthcenteraretrospectivecohortstudy AT chenhillary lowbarriermedicationforopioidusedisorderatafederallyqualifiedhealthcenteraretrospectivecohortstudy AT greinermelissa lowbarriermedicationforopioidusedisorderatafederallyqualifiedhealthcenteraretrospectivecohortstudy AT bushchristopher lowbarriermedicationforopioidusedisorderatafederallyqualifiedhealthcenteraretrospectivecohortstudy AT bhattacharyadebanjan lowbarriermedicationforopioidusedisorderatafederallyqualifiedhealthcenteraretrospectivecohortstudy AT poleystephanie lowbarriermedicationforopioidusedisorderatafederallyqualifiedhealthcenteraretrospectivecohortstudy AT sachdevanidhi lowbarriermedicationforopioidusedisorderatafederallyqualifiedhealthcenteraretrospectivecohortstudy AT crowderjanecarolyn lowbarriermedicationforopioidusedisorderatafederallyqualifiedhealthcenteraretrospectivecohortstudy AT feigaljacob lowbarriermedicationforopioidusedisorderatafederallyqualifiedhealthcenteraretrospectivecohortstudy |